Edition:
United Kingdom

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

40.13USD
4:50pm GMT
Change (% chg)

$0.12 (+0.30%)
Prev Close
$40.01
Open
$40.11
Day's High
$40.27
Day's Low
$39.79
Volume
16,309
Avg. Vol
130,654
52-wk High
$45.49
52-wk Low
$18.25

Select another date:

Mon, Nov 27 2017

BRIEF-Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

* QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS

BRIEF-Quidel Corp reports Q3 GAAP loss per share $0.16

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

BRIEF-Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

* Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

BRIEF-Quidel gets FDA nod for Solana Assay molecular diagnostic test

* Quidel receives FDA clearance for its Solana RSV + hMPV Assay

BRIEF-Quidel Corp says ‍on Oct 6, co entered into credit agreement​

* Quidel corp says ‍on Oct 6, co entered into credit agreement​ - sec filing

BRIEF-QUIDEL ANNOUNCES EARLY TERMINATION OF HART-SCOTT-RODINO WAITING PERIOD ON DEAL FOR ALERE'S ASSAY BUSINESS

* QUIDEL ANNOUNCES EARLY TERMINATION OF THE HART-SCOTT-RODINO WAITING PERIOD FOR ITS PENDING ACQUISITION OF ALERE’S TRIAGE® B-TYPE NATURIETIC PEPTIDE (BNP) ASSAY BUSINESS RUN ON BECKMAN COULTER ANALYZERS

BRIEF-Quidel announces revised agreement for pending acquisition of Alere’s business

* Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers

BRIEF-Quidel Q2 GAAP loss per share $0.35

* Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Quidel announces definitive agreement to acquire Alere Triage assets

* Quidel Corp - ‍accretive transactions extend Quidel's market leadership and position it for future growth​

BRIEF-Quidel receives FDA clearance and CLIA waiver

* Quidel receives FDA clearance and CLIA waiver for its point-of-care sofia 2 instrument for use with sofia respiratory syncytial virus (RSV) assay Source text for Eikon: Further company coverage:

Select another date: